$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414068797 Filed on November 14, 2014

Income Statement

Concept	2014 Q3	2014 Q1	2013 Q3
Revenue	$1.256M	$1.028M	$1.159M
YoY Change	8.37%		82.66%
Cost Of Revenue	$682.0K	$1.046M	$617.0K
YoY Change	10.53%		28.64%
Gross Profit	$575.0K	-$18.00K	$542.0K
YoY Change	6.09%		249.93%
Gross Profit Margin	45.78%	-1.75%	46.76%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$3.584M		$854.8K
YoY Change	319.24%		274.12%
% of Gross Profit	623.23%		157.71%
Depreciation & Amortization	$230.0K	$120.0K	$110.0K
YoY Change	109.09%	33.33%	-8.33%
% of Gross Profit	40.0%		20.3%
Operating Expenses	$4.636M	$2.365M	$1.229M
YoY Change	277.22%		83.39%
Operating Profit	-$4.061M	-$2.384M	-$687.0K
YoY Change	491.12%		33.33%
Interest Expense	$70.08K		$255.9K
YoY Change	-72.62%		317.89%
% of Operating Profit
Other Income/Expense, Net	$10.31M	-$31.65M	-$6.887M
YoY Change	-249.7%		-539.73%
Pretax Income	$21.38M		-$9.635M
YoY Change	-321.89%		-1016.83%
Income Tax	$0.00	-$295.0K	$2.000K
% Of Pretax Income	0.0%
Net Earnings	$6.248M	-$86.80M	-$9.638M
YoY Change	-164.83%		-1017.98%
Net Earnings / Revenue	497.45%	-8443.39%	-831.58%
Basic Earnings Per Share	$0.04	-$0.16	-$0.02
Diluted Earnings Per Share	-$0.01	-$0.16	-$0.02
COMMON SHARES
Basic Shares Outstanding	577.7M shares	618.4M shares	422.0M shares
Diluted Shares Outstanding	739.9M shares		422.0M shares

Balance Sheet

Concept	2014 Q3	2014 Q1	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.630M	$6.940M	$770.0K
YoY Change	890.91%	1775.68%	266.67%
Cash & Equivalents	$7.627M	$6.942M	$766.2K
Short-Term Investments
Other Short-Term Assets	$460.0K	$320.0K	$160.0K
YoY Change	187.5%	113.33%	45.45%
Inventory	$2.520M	$1.932M	$1.720M
Prepaid Expenses
Receivables	$1.100M	$732.1K	$636.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.71M	$9.925M	$3.279M
YoY Change	257.15%	290.22%	141.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.170M	$4.200M	$3.940M
YoY Change	31.21%	4.24%	-5.51%
Goodwill
YoY Change
Intangibles		$6.350M	$6.314M
YoY Change		814.42%
Long-Term Investments	$40.00K	$3.350M	$3.340M
YoY Change	-98.8%	0.3%	0.0%
Other Assets	$610.0K	$3.843M	$540.0K
YoY Change	12.96%	653.61%	1.89%
Total Long-Term Assets	$12.18M	$14.39M	$14.13M
YoY Change	-13.82%	67.72%	62.26%
TOTAL ASSETS
Total Short-Term Assets	$11.71M	$9.925M	$3.279M
Total Long-Term Assets	$12.18M	$14.39M	$14.13M
Total Assets	$23.89M	$24.32M	$17.41M
YoY Change	37.2%	118.58%	72.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.680M	$2.210M	$1.930M
YoY Change	38.86%	66.17%	70.8%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$670.0K	$530.0K	$6.380M
YoY Change	-89.5%	-11.67%
Long-Term Debt Due	$334.9K	$87.57K	$3.390M
YoY Change	-90.12%	-97.42%	-5.57%
Total Short-Term Liabilities	$3.810M	$6.161M	$11.72M
YoY Change	-67.5%	15.0%	146.3%
LONG-TERM LIABILITIES
Long-Term Debt	$233.8K	$18.87K	$0.00
YoY Change
Other Long-Term Liabilities	$73.38M	$131.1K	$96.08K
YoY Change	76275.44%	43.22%	-99.65%
Total Long-Term Liabilities	$75.45M	$99.36M	$11.54M
YoY Change	553.74%	587.99%	-57.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.810M	$6.161M	$11.72M
Total Long-Term Liabilities	$75.45M	$99.36M	$11.54M
Total Liabilities	$79.25M	$105.5M	$23.26M
YoY Change	240.66%	432.95%	-27.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.0M	-$225.0M	-$137.1M
YoY Change	51.68%	75.2%
Common Stock	$153.0M	$144.1M	$131.6M
YoY Change	16.24%	20.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	-$55.36M	-$81.20M	-$5.852M
YoY Change
Total Liabilities & Shareholders Equity	$23.89M	$24.32M	$17.41M
YoY Change	37.2%	118.58%	72.91%

Cashflow Statement

Concept	2014 Q3	2014 Q1	2013 Q3
OPERATING ACTIVITIES
Net Income	$6.248M	-$86.80M	-$9.638M
YoY Change	-164.83%		-1017.98%
Depreciation, Depletion And Amortization	$230.0K	$120.0K	$110.0K
YoY Change	109.09%	33.33%	-8.33%
Cash From Operating Activities	-$4.430M	-$1.480M	-$920.0K
YoY Change	381.52%	572.73%	9.52%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$130.0K	-$90.00K
YoY Change	255.56%	550.0%	-10.0%
Acquisitions
YoY Change
Other Investing Activities	-$50.00K	$60.00K	$50.00K
YoY Change	-200.0%	-25.0%	25.0%
Cash From Investing Activities	-$380.0K	-$70.00K	-$50.00K
YoY Change	660.0%	-216.67%	-16.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$915.0K
YoY Change
Cash From Financing Activities	4.260M	7.400M	1.510M
YoY Change	182.12%	1441.67%	139.68%
NET CHANGE
Cash From Operating Activities	-4.430M	-1.480M	-920.0K
Cash From Investing Activities	-380.0K	-70.00K	-50.00K
Cash From Financing Activities	4.260M	7.400M	1.510M
Net Change In Cash	-550.0K	5.850M	540.0K
YoY Change	-201.85%	1728.12%	-300.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.430M	-$1.480M	-$920.0K
Capital Expenditures	-$320.0K	-$130.0K	-$90.00K
Free Cash Flow	-$4.110M	-$1.350M	-$830.0K
YoY Change	395.18%	575.0%	12.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	26981822	USD
CY2014Q3	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	45885714	USD
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	75446008	USD
CY2014Q3	us-gaap	Liabilities Liabilities	79252113	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	591753	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152380767	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208028632	USD
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-55362954	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23889159	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134083	USD
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	111404	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5508377	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5934888	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	121697	USD
CY2014Q3	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	128785	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	560242430	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	591752031	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	560142430	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	591652031	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1523341	USD
CY2014Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2390825	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	409145	USD
CY2014Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	132792	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1110000	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	106444	USD
CY2014Q3	us-gaap	Long Term Debt LongTermDebt	568766	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18870	USD
CY2014Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	233827	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	87574	USD
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	334939	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1464780	USD
	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	1799971	USD
CY2013Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	921347	USD
CY2014Q3	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	850934	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	404833	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	613128	USD
CY2013Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	231578	USD
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	405483	USD
	us-gaap	Contracts Revenue ContractsRevenue	10972	USD
	us-gaap	Contracts Revenue ContractsRevenue	5000	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	5972	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	272561	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	740611	USD
CY2014Q3	us-gaap	Contracts Revenue ContractsRevenue	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1880585	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2418099	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1158897	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1256417	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1195647	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1410199	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	616635	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	681669	USD
	us-gaap	Gross Profit GrossProfit	684938	USD
	us-gaap	Gross Profit GrossProfit	1007900	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	542262	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	574748	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1424268	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7585508	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	854777	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3565181	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	649018	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1367164	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	28424	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	77143	USD
CY2013Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	18937	USD
CY2014Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	53481	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	245399	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	470696	USD
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	82567	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	276812	USD
	us-gaap	Operating Expenses OperatingExpenses	2347109	USD
	us-gaap	Operating Expenses OperatingExpenses	9500511	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1228842	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	4636085	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1662171	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8492611	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-686580	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4061337	USD
	us-gaap	Interest Expense InterestExpense	330723	USD
	us-gaap	Interest Expense InterestExpense	148281	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	255945	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	70075	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-3233122	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	11121624	USD
CY2013Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-6129579	USD
CY2014Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	10379665	USD
	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-3466332	USD
	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	12823356	USD
CY2013Q3	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-2565495	USD
CY2014Q3	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	15131571	USD
	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	41060	USD
	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	0	USD
CY2013Q3	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	17476	USD
CY2014Q3	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	0	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670678	USD
CY2013Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2014Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7051406	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	3799	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6227485	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	77143	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25467377	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8948664	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25441161	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8713577	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16974766	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9635244	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21379824	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2269	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3248	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2269	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8715846	USD
	us-gaap	Net Income Loss NetIncomeLoss	16978014	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-9637513	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	21379824	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	405073773	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	571455027	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	421991654	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	577691292	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	405073773	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	733633231	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	421991654	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	739869496	shares
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	132610	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	169275	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	143442	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	72609	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	44983	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	5847	USD
CY2014Q2	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	37361487	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	71913	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	203850	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	155169	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	430932	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45169	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	63003	USD
CY2013Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	22584	USD
CY2014Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	45214	USD
CY2013Q3	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	1899	USD
CY2014Q3	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	24010	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	18824	USD
CY2014Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	16437	USD
CY2014Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	7573	USD
	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	initial term that expires on December 31, 2016, and the Company has the option to renew the lease for two additional terms of five years each.
	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.0568	pure
	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Maximum DebtInstrumentInterestRateStatedPercentageRateRangeMaximum	0.0797	pure
	eltp	Interest Expense Non Cash InterestExpenseNonCash	183391	USD
	eltp	Interest Expense Non Cash InterestExpenseNonCash	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	591130	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	5865	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	60861	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	442119	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-183608	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-6667	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-6667	USD
	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-11135	USD
	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1284704	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8641036	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	126478	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1005087	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22261	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16364	USD
	eltp	Stock Issued During Period Value Issued For Capital Purchase Agreement StockIssuedDuringPeriodValueIssuedForCapitalPurchaseAgreement	0	USD
	eltp	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	286231	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2132333	shares
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4810001	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8715846	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16978014	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9637513	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21379824	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	0	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4131412	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	162178204	shares
CY2013Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	222299	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	435537	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	52196	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	154750	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	679771	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	5189	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	708	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	752	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29195	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	365708	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	361527	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8549	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	27642	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	123909	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-176381	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3862456	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6227485	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6250	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	290231	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	137579	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16364	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1858263	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5463881	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	397178	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	685301	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369023	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	65049	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47987	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	766201	USD
	us-gaap	Interest Paid InterestPaid	146624	USD
	us-gaap	Interest Paid InterestPaid	141342	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	495753	USD
CY2014Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2065000	USD
	us-gaap	Other Income OtherIncome	19831	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2013Q3	us-gaap	Other Income OtherIncome	19831	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	260538	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	756053	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	9597945	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2272500	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2014Q3	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	5597317	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
	us-gaap	Notes Issued1 NotesIssued1	5597317	USD
	us-gaap	Notes Issued1 NotesIssued1	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	eltp	Stockissuedduringperiodvaluepaymentofemployeesalaries Stockissuedduringperiodvaluepaymentofemployeesalaries	6190	USD
	eltp	Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue	2272500	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ELTP
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	596612435	shares
CY2014Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	496	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-23944980	USD
CY2013Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
CY2014Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-25511236	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6190	USD

Files In Submission

Name	View Source	Status
0001144204-14-068797-index-headers.html	Edgar Link	pending
0001144204-14-068797-index.html	Edgar Link	pending
0001144204-14-068797.txt	Edgar Link	pending
0001144204-14-068797-xbrl.zip	Edgar Link	pending
eltp-20140930.xml	Edgar Link	completed
eltp-20140930.xsd	Edgar Link	pending
eltp-20140930_cal.xml	Edgar Link	unprocessable
eltp-20140930_def.xml	Edgar Link	unprocessable
eltp-20140930_lab.xml	Edgar Link	unprocessable
eltp-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v393230_10q.htm	Edgar Link	pending
v393230_ex10-82.htm	Edgar Link	pending
v393230_ex31-1.htm	Edgar Link	pending
v393230_ex31-2.htm	Edgar Link	pending
v393230_ex32-1.htm	Edgar Link	pending
v393230_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q3 Form 10-Q Financial Statement

#000114420414068797 Filed on November 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q3 Form 10-Q Financial Statement

#000114420414068797 Filed on November 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp